vTv Therapeutics (VTVT) Projected to Post Quarterly Earnings on Tuesday

vTv Therapeutics (NASDAQ:VTVT) is anticipated to post its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect vTv Therapeutics to post earnings of ($0.87) per share for the quarter.

vTv Therapeutics Price Performance

Shares of NASDAQ VTVT opened at $17.14 on Wednesday. The stock has a market capitalization of $54.68 million, a P/E ratio of -3.78 and a beta of 1.07. vTv Therapeutics has a one year low of $12.12 and a one year high of $30.99. The firm’s 50 day simple moving average is $16.16 and its two-hundred day simple moving average is $15.34.

Wall Street Analyst Weigh In

Several equities analysts recently commented on VTVT shares. StockNews.com assumed coverage on shares of vTv Therapeutics in a report on Monday. They set a “sell” rating on the stock. Alliance Global Partners started coverage on vTv Therapeutics in a research note on Monday, December 9th. They set a “buy” rating and a $35.00 price objective on the stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.